Review



human non small cell lung carcinoma nsclc cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC human non small cell lung carcinoma nsclc cell lines
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Non Small Cell Lung Carcinoma Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9076 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/A549/bio_rxiv__64898__2026__02__17__706284-49-0-26
    Average 99 stars, based on 9076 article reviews
    human non small cell lung carcinoma nsclc cell lines - by Bioz Stars, 2026-09
    99/100 stars

    Images

    1) Product Images from "The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer"

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    Journal: bioRxiv

    doi: 10.64898/2026.02.17.706284

    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Figure Legend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

    Techniques Used: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY


    Figure Legend Snippet:

    Techniques Used: Inhibition, Mutagenesis

    (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.
    Figure Legend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

    Techniques Used: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

    (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.
    Figure Legend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

    Techniques Used: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification



    Similar Products

    human non small cell lung carcinoma nsclc cell lines  (ATCC)
    99
    ATCC human non small cell lung carcinoma nsclc cell lines
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Non Small Cell Lung Carcinoma Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/A549/bio_rxiv__64898__2026__02__17__706284-49-0-26
    Average 99 stars, based on 1 article reviews
    human non small cell lung carcinoma nsclc cell lines - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    small cell lung cancer cell nsclc line h1650  (ATCC)
    94
    ATCC small cell lung cancer cell nsclc line h1650
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Small Cell Lung Cancer Cell Nsclc Line H1650, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/NCI-H1650+(H1650)%3B+Bronchoalveolar+carcinoma%3B+Human/pm40740057-196-1-12
    Average 94 stars, based on 1 article reviews
    small cell lung cancer cell nsclc line h1650 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    non small cell lung carcinoma nsclc cell line a549  (ATCC)
    97
    ATCC non small cell lung carcinoma nsclc cell line a549
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Non Small Cell Lung Carcinoma Nsclc Cell Line A549, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/A-549%3B+Lung+Carcinoma%3B+Human/pmc11103505__thnov14p2656s1-0-30-41
    Average 97 stars, based on 1 article reviews
    non small cell lung carcinoma nsclc cell line a549 - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    non small cell lung carcinoma nsclc derived cell line  (ATCC)
    96
    ATCC non small cell lung carcinoma nsclc derived cell line
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Non Small Cell Lung Carcinoma Nsclc Derived Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/Human+small+cell+lung+cancer+cell+Line+H69PR/pmc11628339-45-20-35
    Average 96 stars, based on 1 article reviews
    non small cell lung carcinoma nsclc derived cell line - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    human non-small-cell lung carcinoma (nsclc) cell lines (a549  (DSMZ)
    90
    DSMZ human non-small-cell lung carcinoma (nsclc) cell lines (a549
    Effect of pure GEF, Plain-SLN, GEF-SLN, and GEF-P-SLN on cell viability <t>of</t> <t>A549</t> cell line using MTT assay treated with different concentrations (2.5, 5, 10, and 20 μg/mL) after 48 h.
    Human Non Small Cell Lung Carcinoma (Nsclc) Cell Lines (A549, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/A-549/pmc09342893-176-0-11
    Average 90 stars, based on 1 article reviews
    human non-small-cell lung carcinoma (nsclc) cell lines (a549 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    nci h460 human non small cell lung cancer nsclc carcinoma cell line  (ATCC)
    95
    ATCC nci h460 human non small cell lung cancer nsclc carcinoma cell line
    Effect of pure GEF, Plain-SLN, GEF-SLN, and GEF-P-SLN on cell viability <t>of</t> <t>A549</t> cell line using MTT assay treated with different concentrations (2.5, 5, 10, and 20 μg/mL) after 48 h.
    Nci H460 Human Non Small Cell Lung Cancer Nsclc Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/NCI-H460%3B+Lung+Carcinoma%3B+Human/pm35073699__nl1c03786_si_001-45-0-12
    Average 95 stars, based on 1 article reviews
    nci h460 human non small cell lung cancer nsclc carcinoma cell line - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    a549 human non-small cell lung carcinoma (nsclc) cell lines  (National Centre for Cell Science)
    90
    National Centre for Cell Science a549 human non-small cell lung carcinoma (nsclc) cell lines
    Representation of deregulation of miRNAs during <t>NSCLC</t> aiding in tumor progression.
    A549 Human Non Small Cell Lung Carcinoma (Nsclc) Cell Lines, supplied by National Centre for Cell Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+non+small+cell+lung+carcinoma+nsclc+cell+lines/a549/pmc09131939-283-0-13
    Average 90 stars, based on 1 article reviews
    a549 human non-small cell lung carcinoma (nsclc) cell lines - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet:

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Inhibition, Mutagenesis

    (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

    (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification

    Effect of pure GEF, Plain-SLN, GEF-SLN, and GEF-P-SLN on cell viability of A549 cell line using MTT assay treated with different concentrations (2.5, 5, 10, and 20 μg/mL) after 48 h.

    Journal: International Journal of Nanomedicine

    Article Title: PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

    doi: 10.2147/IJN.S365974

    Figure Lengend Snippet: Effect of pure GEF, Plain-SLN, GEF-SLN, and GEF-P-SLN on cell viability of A549 cell line using MTT assay treated with different concentrations (2.5, 5, 10, and 20 μg/mL) after 48 h.

    Article Snippet: Human non-small-cell lung carcinoma (NSCLC) cell lines (A549) were obtained from DSMZ Leibniz Institute (German Collection of Microorganisms and Cell Cultures Braunschweig, Germany).

    Techniques: MTT Assay

    IC50 for All Formulations on the A549 Cells Using MTT Assay

    Journal: International Journal of Nanomedicine

    Article Title: PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

    doi: 10.2147/IJN.S365974

    Figure Lengend Snippet: IC50 for All Formulations on the A549 Cells Using MTT Assay

    Article Snippet: Human non-small-cell lung carcinoma (NSCLC) cell lines (A549) were obtained from DSMZ Leibniz Institute (German Collection of Microorganisms and Cell Cultures Braunschweig, Germany).

    Techniques:

    Flow cytometric analysis of A549 cell line treated with ( A ) Control, ( B ) Plain-SLN, ( C ) pure GEF, and ( D ) GEF-P-SLN at 3.5 μg/mL concentration. (A1, A2, A3, and A4) Necrotic, late apoptotic, early apoptotic, and viable cells are shown in the upper left quadrant, upper right quadrant, lower right quadrant, and lower left quadrant, respectively. ( E ) Bar chart shows the percentage of live, early apoptosis, late apoptosis, and necrotic cells that were treated with control, Plain-SLN, pure GEF, and GEF-P-SLN.

    Journal: International Journal of Nanomedicine

    Article Title: PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer

    doi: 10.2147/IJN.S365974

    Figure Lengend Snippet: Flow cytometric analysis of A549 cell line treated with ( A ) Control, ( B ) Plain-SLN, ( C ) pure GEF, and ( D ) GEF-P-SLN at 3.5 μg/mL concentration. (A1, A2, A3, and A4) Necrotic, late apoptotic, early apoptotic, and viable cells are shown in the upper left quadrant, upper right quadrant, lower right quadrant, and lower left quadrant, respectively. ( E ) Bar chart shows the percentage of live, early apoptosis, late apoptosis, and necrotic cells that were treated with control, Plain-SLN, pure GEF, and GEF-P-SLN.

    Article Snippet: Human non-small-cell lung carcinoma (NSCLC) cell lines (A549) were obtained from DSMZ Leibniz Institute (German Collection of Microorganisms and Cell Cultures Braunschweig, Germany).

    Techniques: Concentration Assay

    Representation of deregulation of miRNAs during NSCLC aiding in tumor progression.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Representation of deregulation of miRNAs during NSCLC aiding in tumor progression.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques:

    Enrichment analysis of miR-520c-3p in BEAS-2B vs. A549 cells is represented.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Enrichment analysis of miR-520c-3p in BEAS-2B vs. A549 cells is represented.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques:

    Heat-map generated for identified down-regulated miRNAs during NSCLC.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Heat-map generated for identified down-regulated miRNAs during NSCLC.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques: Generated

    Frequently mutated genes during NSCLC vs. percentage of cases affected.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Frequently mutated genes during NSCLC vs. percentage of cases affected.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques:

    Expression Plots of ( A ) AKT1, ( B ) AKT2, ( C ) CDC2, ( D ) NFKB1, ( E ) TP53, ( F ) PDK1, ( G ) PDK2, ( H ) PI3K and ( I ) PTEN, respectively. The Kaplan Meier Plotter database evaluated the predictive impact of AKT1, AKT2, CDC2, NF-κB, TP53, PDPK1, PDK2, PI3K and PTEN expression NSCLC development. The red line indicates patients with expressions above the median, whereas the black line indicates patients below.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Expression Plots of ( A ) AKT1, ( B ) AKT2, ( C ) CDC2, ( D ) NFKB1, ( E ) TP53, ( F ) PDK1, ( G ) PDK2, ( H ) PI3K and ( I ) PTEN, respectively. The Kaplan Meier Plotter database evaluated the predictive impact of AKT1, AKT2, CDC2, NF-κB, TP53, PDPK1, PDK2, PI3K and PTEN expression NSCLC development. The red line indicates patients with expressions above the median, whereas the black line indicates patients below.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques: Expressing

    Survival Analysis of ( A ) AKT1, AKT2, AKT3; ( B ) MTOR; ( C ) NF-κB, RelA; ( D ) PDK1; ( E ) PI3K; ( F ) PTEN with survival time period. Red colored line represents the high expression and Blue colored line depicts low expression of the respective genes during NSCLC.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: Survival Analysis of ( A ) AKT1, AKT2, AKT3; ( B ) MTOR; ( C ) NF-κB, RelA; ( D ) PDK1; ( E ) PI3K; ( F ) PTEN with survival time period. Red colored line represents the high expression and Blue colored line depicts low expression of the respective genes during NSCLC.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques: Expressing

    The differential expression of ( A ) AKT1, ( B ) AKT2, ( C ) mTOR, ( D ) RELA, ( E ) PDK1, ( F ) PDK2, ( G ) PTEN, ( H ) TP53 targeted genes during NSCLC in different progression states ranging from tumors to normal. The statistical significance of differential expression of genes is shown as p -value.

    Journal: Oncotarget

    Article Title: Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach

    doi: 10.18632/oncotarget.28233

    Figure Lengend Snippet: The differential expression of ( A ) AKT1, ( B ) AKT2, ( C ) mTOR, ( D ) RELA, ( E ) PDK1, ( F ) PDK2, ( G ) PTEN, ( H ) TP53 targeted genes during NSCLC in different progression states ranging from tumors to normal. The statistical significance of differential expression of genes is shown as p -value.

    Article Snippet: A549 human non-small cell lung carcinoma (NSCLC) cell lines obtained from Cell Repository, National Centre for Cell Science, Pune.

    Techniques: Quantitative Proteomics